MedTrace Logo

Early Diagnosis of Gastric Cancer Cachexia

NCT06277986 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-02-26

No results posted yet for this study

Summary

Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. In cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. Therefore, it is important to find biomarkers for early detection of cachexia. The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.

Conditions

  • Cachexia

Interventions

OTHER

cachexia

Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2024-09-01
Completion
2024-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277986 on ClinicalTrials.gov